MDRNA has appointed Barry Polisky as its CSO.
Polisky will replace Steven Quay, who will be stepping down from his roles as CSO and chairman of the company’s board of directors and scientific advisory board.
Previously, Polisky served as research vice president of Merck. He also served as CSO of Sirna Therapeutics prior to its acquisition by Merck. He holds a PhD in molecular biology from the University of Colorado.
MDRNA also announced that Bruce Thaw, lead independent director of the company, will assume the role of chairman of the board. James Rothman, a member of MDRNA’s scientific advisory board, has also been named chairman of the SAB.
In conjunction with the appointments, MDRNA said that former President, CEO, and Chairman Steven Quay will step down from the company. He will remain a member of both boards.